Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 67Pancreatic Neoplasms 34Neoplasm Metastasis 22Neuroblastoma 21Neoplasms 16Colonic Neoplasms 15Stomach Neoplasms 13Rectal Neoplasms 13Sarcoma, Ewing 8Rhabdomyosarcoma 8Esophageal Squamous Cell Carcinoma 8Small Cell Lung Carcinoma 7Sarcoma 7Ovarian Neoplasms 6Lung Neoplasms 6Cholangiocarcinoma 6Esophageal Neoplasms 5Breast Neoplasms 5Adenocarcinoma Of Esophagus 5Medulloblastoma 4Gastrointestinal Neoplasms 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Adenocarcinoma 4Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Osteosarcoma 3Glioma 3Glioblastoma 3Ganglioneuroblastoma 3

Interventions

temsirolimus 1ixabepilone 1Vorinostat 1Taxes 1Sirolimus 1Paclitaxel 1Irinotecan 1Erlotinib Hydrochloride 1Epothilones 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adult Solid Neoplasm × Irinotecan × 1 year × Clear all
NCT00045201 2026-04-13

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
60 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡